TWA
ACRS icon

TCI Wealth Advisors’s Aclaris Therapeutics ACRS Stock Holding History

TCI Wealth Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-528
Closed -$4.27K – 225
2023
Q1 		$4.27K Buy
+528
New +$6.7K ﹤0.01% 1636
2022
Q1 		– Sell
-309
Closed -$4K – 2198
2021
Q4 		$4K Buy
309
+106
+52% +$1.61K ﹤0.01% 1766
2021
Q3 		$4K Buy
+203
New +$3.25K ﹤0.01% 1693

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCI Wealth Advisors's ACRS Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Aclaris Therapeutics (ACRS) in Q2 2023, closing a stake of 528 shares — an estimated $4.27K sold.

TCI Wealth Advisors first reported a position in ACRS in Q3 2021 and held it in 3 quarters. The position peaked at $4.27K in Q1 2023. 133 funds tracked by Wall St. Rank hold ACRS as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Aclaris Therapeutics position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 528 Aclaris Therapeutics shares in Q2 2023, an estimated $4.27K.
  • TCI Wealth Advisors first reported a position in Aclaris Therapeutics in Q3 2021 and held it in 3 quarters.
  • TCI Wealth Advisors's Aclaris Therapeutics position peaked at $4.27K in Q1 2023.
  • 133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.